A. Davis
Director/Board Member at ACASTI PHARMA INC.
Net worth: - $ as of 2024-06-29
Profile
Mr. A.
B.
Davis is a Chief Financial Officer & IR Contact at Cortendo AB and a Chief Financial Officer at Xylocor Therapeutics, Inc. He is on the Board of Directors at Acasti Pharma, Inc. Mr. Davis was previously employed as a Chief Financial & Accounting Officer by Verrica Pharmaceuticals, Inc., a Chief Financial & Accounting Officer by Strongbridge Biopharma Plc, a CFO, Secretary & Senior Vice President-Finance by Tengion, Inc., a Chief Financial Officer & Senior Vice President by Neose Technologies, Inc., and a Controller by MICRO Healthsystems, Inc. He received his undergraduate degree from The College of New Jersey and an MBA from The Wharton School of the University of Pennsylvania.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2024-05-30 | 0 ( -.--% ) | - $ | 2024-06-29 |
A. Davis active positions
| Companies | Position | Start |
|---|---|---|
| ACASTI PHARMA INC. | Director/Board Member | 2023-10-09 |
Cortendo AB
 Cortendo AB Miscellaneous Commercial ServicesCommercial Services Cortendo AB engages in the provision of biopharmaceutical business. Its activities include development and distribution of orphan drugs for metabolic and endocrine diseases as well as diabetes. Its products include cortisol inhibition and normocort. The company was founded on October 6, 1996 and is headquartered in Trevose, PA. | Director of Finance/CFO | 2015-03-22 |
Xylocor Therapeutics, Inc.
 Xylocor Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Xylocor Therapeutics, Inc. engages in the biopharmaceutical company that develops gene therapy for people with advanced coronary artery disease. It focuses on developing product for patients with refractory angina with no treatment options and its secondary product for patients with cardiac tissue damage from heart attacks. The company was founded by Ronald Crystal and Todd Rosengart in 2013 and is headquartered in Malvern, PA. | Director of Finance/CFO | - |
Former positions of A. Davis
| Companies | Position | End |
|---|---|---|
| VERRICA PHARMACEUTICALS INC. | Director of Finance/CFO | 2021-07-15 |
| STRONGBRIDGE BIOPHARMA | Director of Finance/CFO | 2019-09-02 |
| TENGION, INC. | Director of Finance/CFO | 2014-12-30 |
Neose Technologies, Inc.
 Neose Technologies, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activity is to develop proprietary drugs, focusing primarily on therapeutic proteins. Its technologies to develop proprietary versions of protein drugs with proven safety and efficacy and to improve the therapeutic profiles of proteins being developed. Its proprietary drug development portfolio currently consists of two therapeutic protein candidates.GlycoPEG-EPO (NE-180) is a long-acting version of erythropoietin (EPO) produced in insect cells. EPO is prescribed to stimulate production of red blood cells, and it gives treatment of chemotherapy-induced anemia and anemia associated with chronic renal failure. Its second proprietary protein, GlycoPEG-GCSF, is a long-acting version of granulocyte colony stimulating factor G-CSF and it is prescribed to stimulate production of neutrophils (a type of white blood cell). Its trademarks are NEOSE, GlycoPEGylation and GlycoConjugation. It operates predominantly in the domestic market. | Director of Finance/CFO | 2010-07-07 |
MICRO Healthsystems, Inc.
 MICRO Healthsystems, Inc. Packaged SoftwareTechnology Services MICRO Healthsystems, Inc. develops operating systems computer software. The private company is based in West Orange, NJ and has subsidiaries in the United States. | Comptroller/Controller/Auditor | 1993-12-31 |
Training of A. Davis
| The College of New Jersey | Undergraduate Degree |
| The Wharton School of the University of Pennsylvania | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 3 |
|---|---|
| TENGION, INC. | Health Technology |
| ACASTI PHARMA INC. | Health Technology |
| VERRICA PHARMACEUTICALS INC. | Health Technology |
| Private companies | 5 |
|---|---|
MICRO Healthsystems, Inc.
MICRO Healthsystems, Inc. Packaged SoftwareTechnology Services MICRO Healthsystems, Inc. develops operating systems computer software. The private company is based in West Orange, NJ and has subsidiaries in the United States. | Technology Services |
Neose Technologies, Inc.
Neose Technologies, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activity is to develop proprietary drugs, focusing primarily on therapeutic proteins. Its technologies to develop proprietary versions of protein drugs with proven safety and efficacy and to improve the therapeutic profiles of proteins being developed. Its proprietary drug development portfolio currently consists of two therapeutic protein candidates.GlycoPEG-EPO (NE-180) is a long-acting version of erythropoietin (EPO) produced in insect cells. EPO is prescribed to stimulate production of red blood cells, and it gives treatment of chemotherapy-induced anemia and anemia associated with chronic renal failure. Its second proprietary protein, GlycoPEG-GCSF, is a long-acting version of granulocyte colony stimulating factor G-CSF and it is prescribed to stimulate production of neutrophils (a type of white blood cell). Its trademarks are NEOSE, GlycoPEGylation and GlycoConjugation. It operates predominantly in the domestic market. | Health Technology |
Cortendo AB
Cortendo AB Miscellaneous Commercial ServicesCommercial Services Cortendo AB engages in the provision of biopharmaceutical business. Its activities include development and distribution of orphan drugs for metabolic and endocrine diseases as well as diabetes. Its products include cortisol inhibition and normocort. The company was founded on October 6, 1996 and is headquartered in Trevose, PA. | Commercial Services |
Strongbridge Biopharma Plc
 Strongbridge Biopharma Plc Pharmaceuticals: MajorHealth Technology Strongbridge Biopharma Plc operates as a commercial-stage biopharmaceutical company, which focuses on the development and commercialization of therapies for rare diseases. Its pipeline is comprised of Keveyis, Macrilen, Recorlev, and Veldoreotide. The company was founded in 1996 and is headquartered in Trevose, PA. | Health Technology |
Xylocor Therapeutics, Inc.
Xylocor Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Xylocor Therapeutics, Inc. engages in the biopharmaceutical company that develops gene therapy for people with advanced coronary artery disease. It focuses on developing product for patients with refractory angina with no treatment options and its secondary product for patients with cardiac tissue damage from heart attacks. The company was founded by Ronald Crystal and Todd Rosengart in 2013 and is headquartered in Malvern, PA. | Health Technology |
- Stock Market
- Insiders
- A. Davis
